- Home
- VRNA
VRNA
Verona Pharma plc
as 02-21-2025 4:00pm EST
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Upcoming Earnings Alert:
Get ready for potential market movements as Verona Pharma plc VRNA prepares to release earnings report on 27 Feb 2025.
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 3.4B | IPO Year: | 2017 |
| Target Price: | $57.14 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.39 - $68.64 | Next Earning Date: | 02-27-2025 |
| Revenue: | $5,624,000 | Revenue Growth: | 1127.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 571.44% |
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | VRNA | President and CEO | Dec 4 '24 | Sell | $5.01 | 870,672 | $4,358,787.38 | 14,204,752 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Dec 4 '24 | Sell | $5.01 | 881,960 | $4,415,451.86 | 13,293,736 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Nov 27 '24 | Sell | $5.00 | 125,328 | $627,233.33 | 14,204,752 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Nov 27 '24 | Sell | $5.00 | 113,240 | $566,821.84 | 13,293,736 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Nov 25 '24 | Sell | $5.00 | 1,600 | $8,000.00 | 14,204,752 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Nov 25 '24 | Sell | $5.00 | 2,400 | $12,000.00 | 13,293,736 | |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | Nov 25 '24 | Sell | $4.90 | 240,000 | $1,176,360.00 | 2,671,480 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Verona Pharma Announces March 2025 Investor Conference Participation
GlobeNewswire
9 days ago
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
Zacks
10 days ago
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
Zacks
a month ago
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
Insider Monkey
a month ago
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
Investor's Business Daily
a month ago
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week
Zacks
a month ago
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
Zacks
a month ago
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Compare VRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRNA Verona Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.